1179 Hepatitis B virus genotypes B and C do not affect the anti-viral response to lamivudine

Yuen, Man‐Fung; Wong, Danny Ka‐Ho; Sablon, Erwin; Yuan, Huijuan; Sum, Simon Siu-Man; Hui, Chee–Kin; Wong, Benjamin Chun–Yu; Lai, Ching–Lung

doi:10.1016/s0270-9139(03)81217-x

Cited by 52 publications

(72 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of YMDD variants, the methionine (M) is substituted with either isoleucine (I), designated as YIDD, or valine (V), called YVDD (57), which can emerge in 15z of patients in 1 year and in 50z in 3 years after the initiation of therapy (58) and could be followed by hepatic failure, i.e., breakthrough hepatitis (59). In the Hong Kong study, there was no difference in the antiviral response and rate of developing YMDD mutations in 82 patients with chronic hepatitis B with genotypes B and C after 1 year of lamivudine treatment (60). In Guiyang, there is a report on 87 patients receiving lamivudine, and even The available data could only be reliably between genotypes A and D. AHB, acute hepatitis B; FHB, fulminant hepatitis B; CHB, chronic hepatitis B.…”

Section: -1 Clinical Differences Of Hbv Genotypesmentioning

confidence: 99%

Correlation between Hepatitis B Virus Genotypes and Clinical Outcomes

Shi¹

2012

Jpn J Infect Dis

View full text Add to dashboard Cite

Section: -1 Clinical Differences Of Hbv Genotypesmentioning

confidence: 99%

Correlation between Hepatitis B Virus Genotypes and Clinical Outcomes

Shi¹

2012

Jpn J Infect Dis

View full text Add to dashboard Cite

“…On the whole, there seems to be little evidence for genotype-dependent responses to these agents. For lamivudine treatment of HBeAg ϩ CHB, information is available primarily for genotypes B and C. There are strong data demonstrating no effect of genotype (B versus C) on lamivudine response, including equivalent rates of HBeAg seroconversion, log HBV DNA reduction, and median aminotransferase normalization 12 months after end of therapy (163). Another study, measuring similar parameters at the same times (22), showed a greater sustained response in genotype B than in genotype C patients; however, the ratio of genotype B to C patients in this study was 3:1, introducing a potential for bias in the results.…”

Section: Hbv Genotyping: Utilitymentioning

confidence: 99%

Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B

Valsamakis

2007

Clin Microbiol Rev

137

View full text Add to dashboard Cite

SUMMARY Hepatitis B virus (HBV) is an enveloped virus with a small (3.2-kb) partially double-stranded DNA genome that causes acute and chronic infections. The impact of these infections on public health worldwide is enormous, with an estimated prevalence of 2 billion acute infections and 360 million chronic infections globally. This review focuses on chronic hepatitis B and the molecular assays used in its diagnosis and management. Background information, including that about features of the hepatitis B virion, viral replication, and epidemiology of infection, that is important for understanding chronic hepatitis B and molecular diagnostic tests for HBV is provided. To facilitate an understanding of the utility of molecular testing for chronic hepatitis B, the four stages of chronic hepatitis B infection that are currently recognized, as well as an additional entity, occult hepatitis B, that can be diagnosed only by sensitive nucleic acid amplification methods, are reviewed in detail, including available therapeutic agents. The molecular diagnostic content focuses on tests for HBV DNA quantification, genotyping, and mutation detection (including precore/core promoter and antiviral resistance mutations). The discussion of these tests encompasses their current utility and performance characteristics, drawing from current clinical guidelines and other studies from the literature. In recognition of the continual evolution of this field, the final section describes emerging molecular markers with future diagnostic potential.

show abstract

“…In patients treated with lamivudine, previous studies from Taiwan and Hong Kong indicated that HBV genotype had no impact on the therapeutic response to lamivudine [119][120][121]. In Spain, Buti et al suggested that the outcome after lamivudine treatment was also comparable between genotypes A and D [122].…”

Section: Genotypesmentioning

confidence: 99%

Role of viral factors in the natural course and therapy of chronic hepatitis B

Kao

2007

Hepatol Int

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is a global health problem that causes a wide spectrum of liver disease, including acute or fulminant hepatitis, inactive carrier state, chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). The pathogenesis of hepatocyte damage associated with HBV is mainly through immune-mediated mechanisms. On the basis of the virus and host interactions, the natural history of HBV carriers who are infected in early life can be divided into four dynamic phases. The frequency, extent, and severity of hepatitis flares or acute exacerbation in the second immune clearance and/or fourth reactivation phase predict liver disease progression in HBV carriers. In the past decade, hepatitis B viral factors including serum HBV DNA level, genotype, and naturally occurring mutants predictive of clinical outcomes have been identified. The higher the serum HBV DNA level after the immune clearance phase, the higher the incidence of adverse outcomes over time. In addition, high viral load, genotype C, basal core promoter mutation, and pre-S deletion correlate with increased risk of cirrhosis and HCC development. As to the treatment of chronic hepatitis B, patients with high HBV DNA level and genotype C or D infection are shown to have a worse response to interferon therapy. In conclusion, serum HBV DNA level, genotype, and naturally occurring mutants are identified to influence liver disease progression and therapy of chronic hepatitis B. More investigations are needed to clarify the molecular mechanisms of the viral factors involved in the pathogenesis of each stage of liver disease and the response to antiviral treatments.

show abstract

1179 Hepatitis B virus genotypes B and C do not affect the anti-viral response to lamivudine

Cited by 52 publications

References 0 publications

Correlation between Hepatitis B Virus Genotypes and Clinical Outcomes

Correlation between Hepatitis B Virus Genotypes and Clinical Outcomes

Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B

Role of viral factors in the natural course and therapy of chronic hepatitis B

Contact Info

Product

Resources

About